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Background: The Unified Airways hypothesis suggests an involvement of the upper airways in
asthma. Critical parameters of the nasal airway can be quantified objectively with acoustic rhi-
nometry (AR) and peak nasal inspiratory flow (PNIF).
Objective: We aimed to investigate nasal airway patency in asthmatics compared to non-
asthmatic controls. Nasal volume, cross sectional area and flow were measured using acoustic
rhinometry (AR) and peak nasal inspiratory flow (PNIF) in 87 asthmatics and 93 non-asthmatic
controls before and after decongestion with xylometazoline. Nasal congestion index (NCI) was
calculated, and allergy status was assessed by skin prick test or specific IgE.
Results: We found significantly smaller minimum cross sectional area and nasal cavity volume
in asthmatics than controls, and the cross sectional area is at its minimum at 2e3 cm from the
nasal orifice in both groups. AR and PNIF measurements are not different in allergic and non
allergic subjects in either group. The effect of xylometazoline is not significantly different be-
tween the 2 groups with regard to AR, but there is a significant improvement in PNIF for the
asthmatics when assessed by the NCI.olaryngology, Head and Neck Surgery, St Olavs Hospital, University Hospital of Trondheim, 7006
4 78/91 11 42 22; fax: þ47 72 57 57 66.
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1516 W.M. Thorstensen et al.Conclusion: The present study demonstrates a significantly smaller nasal airway when assessed
by minimum cross sectional area and nasal cavity volume in asthmatics than controls, and
these findings apply to asthmatics and controls irrespective of allergy status.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The Unified Airways hypothesis suggests an involvement of
the upper airways in asthma [1e3]. Rhinitis typically pre-
cedes the development of asthma and can contribute to
unsatisfactory asthma control. Nasal symptoms, airflow,
and markers of inflammation directly correlate with lower
airway involvement [4]. In both rhinitis and asthma, an
inflammatory cell infiltrate with subepithelial oedema is
present in the mucosa [5]. Unlike the lower airway, the
nasal mucosa contains venous sinusoids that undergo peri-
odic congestion and decongestion (the nasal cycle) that are
important for regulation of airflow, humidification and
warming of the inspired air. Nasal obstruction may be
indicative of structural deformities, infections and inflam-
matory conditions in the nose, and is frequently reported
by asthmatics [6]. Their lack of nasal patency may also be
due to factors such as mucosal congestion and changed
perception of flow.
Critical parameters of the nasal airway can be quantified
objectively with acoustic rhinometry (AR) and peak nasal
inspiratory flow (PNIF) [7,8]. While the former measures
internal nasal volume and minimum cross-sectional areas,
the latter measures the maximum nasal inspiratory flow
during forced inspiration. The Nasal Congestion Index (NCI)
has been suggested as a useful instrument for the evalua-
tion of nasal obstruction by quantifying the effect of topical
decongestants applied on the nasal mucosa [9]. There are
few studies that have used these tools to investigate the
relative contribution of subepithelial oedema and conges-
tion of the venous sinusoids in asthmatics. Hellgren et al.
[10] demonstrated increased nasal mucosal swelling in
asthmatics compared to healthy controls.
In this study, we measured nasal volume, cross sectional
area and flow using AR and PNIF, and assessed the effect of
xylometazoline using the NCI in order to further elucidate
the role of oedema and congestion in the nasal mucosa of
asthmatics.
Methods
Subjects
The study consisted of 87 patients with asthma, and they
were recruited from the out-patients’ clinic at the
Department of Lung Medicine, St Olavs Hospital, University
Hospital of Trondheim. The asthma diagnosis was based on
the presence of typical asthma symptoms, with either 12%
and 200 ml improvement of forced expiratory volume in
the first second (FEV1) from baseline after inhalation of
salbutamol or positive methacholine bronchial provocation
test (PD20 FEV1  1600 mg) and in accordance with the
British Thoracic Society criteria [11].Ninety-three non-asthmatic controls were mostly
recruited from the out-patients’ clinic of Department of
Otolaryngology, Head and Neck Surgery, St Olavs Hospital,
University Hospital of Trondheim, among patients with dis-
orders not affecting the upper airways (e.g. external otitis,
and skin diseases in the ENT area). Some controls were also
randomly invited from nearby businesses with all types of
employments, from manual labour to skilled work. The sam-
ple, allergy status, questionnaires and additional recordings
were based on a database that has previously been described
[6]. Exclusion criteria were the presence of acute and chronic
rhinosinusitis and nasal polyposis on oto-rhino-laryngological
examination and in accordance to the EPOS 2012 criteria
[12], pregnancy, previous nasal surgery, systemic diseasewith
potential affection of the nose, such as Wegener’s gran-
ulomatosis, cystic fibrosis, primary ciliary dyskinesia, Karta-
gener’s syndrome and sarcoidosis, and a history of cancer. For
the NCI we analyzed 85 patients with asthma and 93 non-
asthmatic controls. The missing values were discarded
because of one patient with missing decongested values and
one patient was resistant to accept topical xylometazoline.
The study was approved by the Regional Committee for
Medical Research Ethics, and conducted according to the
Helsinki Declaration.Written informed consentwas obtained.AR
AR is a sonic echo technique which was used to measure the
nasal volumes and minimal cross sectional areas. Nasal
passage volumes are calculated from contiguous cross-
sectional values.
The measurements were made with an impulse acoustic
rhinometer (RhinoMetrics SRE2100, Rhinoscan version 2.5,
built 3.2.5.0; Interacoustics, Minneapolis, MN) by two
trained operators throughout the study. The probe was
hand held with the subject sitting upright and opposite to
the investigator. An appropriate anatomic nose adaptor and
contact gel between the nose adaptor and the nostril were
used, and measurements were made during a breath hold.
Recordings were performed according to published pro-
tocols [13]. Briefly, three satisfactory recordings were
made from each nasal cavity. The values for each nasal
cavity were averaged. Due to the variations represented by
the nasal cycle, the sum of the two averages was divided by
2 to obtain the minimal cross sectional area (MCA, cm2) and
nasal cavity volume (NCV, cm3). The rhinometer was pro-
grammed to calculate the MCA0e3 and MCA3e5.2, and NCV0e3
and NCV3e5.2, defined as MCA and NCV at 0e3 cm and
3e5.2 cm, respectively from the nasal orifice. MCA0e5.2 is
the minimum cross sectional area at 0e5.2 cm from the
nasal orifice. NCV0e5.2 is the sum of NCV0e3 and NCV3e5.2.
After visual inspection of the rhinometric curves, the
rhinometer was reprogrammed to calculate MCA0e2 and
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2e4 cm, respectively from the nasal orifice. MCA0e4 is the
minimum cross sectional area at 0e4 cm from the nasal
orifice. NCV0e4 is the sum of NCV0e2 and NCV2e4.
PNIF
Peak nasal inspiratory flow was assessed with a portable
PNIF meter (In-check DIAL; Clement Clarke International,
Harlow, Essex, UK). The average of three satisfactory
maximal nasal inspirations with the patient in the sitting
position was recorded.
Maximum flow registration was limited to 120 l/min. Peak
flows exceeding 120 l/min were recorded as 120 l/min.
Nasal decongestion
After baseline recordings of AR and PNIF, the nasal mucosa
was decongested with two sprays of topical xylometazoline
(OtrivinVR 1 mg/ml, Novartis, Basel, Switzerland) applied in
a standardized manner with a hand pump to each nasal
cavity. Recordings of AR and PNIF were repeated after
10 min.
NCI
The effect of topical xylometazoline on MCA, NCV and PNIF
was assessed by calculating the Nasal Congestion Index [9]
for each variable using the following equation: NCIZ (post
xylometazoline value  baseline value)/baseline value.
A low NCI indicates minor mucosal congestion as
opposed to a high NCI which suggests a high degree of
reversible mucosal congestion.
Allergy
Sensitization to house dust mite, cat, dog, horse, timothy
grass and birch pollens, mugwort and cladosporium was
assessed with either specific IgE measurement (AlaTOP,
Diagnostic Products Corporation, Los Angeles, California,
USA) or skin prick tests (Soluprick SQ, ALK-Abello, Hor-
sholm, Denmark). Antihistamines were discontinued 4 days
prior to skin prick tests. Subjects with typical symptoms of
hypersensitivity on exposure to the allergen(s) and positive
tests were classified as allergic.
Statistics
The data were tested for normal distribution using normal
probability plots and presented as mean, standardTable 1 Patient demographics.
Asthmatics,
N Z 87
Controls,
N Z 93
Mean age, years (range) 43.7 (19e64) 44.0 (20e65)
Mean BMI, kg/m2 (SD) 26.8 (5.0) 25.2 (3.3)
Gender, Male, n (%) 36 (41) 41 (44)
Allergy, n (%) 52 (60) 20 (22)
Smoking, n (%) 9 (10) 12 (13)deviation (SD) or 95% confidence interval (95% CI). The in-
dependent samples t test was used to evaluate differences
in mean values in the asthmatic and control groups. Anal-
ysis of variance (ANOVA) with the post hoc application of
Bonferroni correction was used to assess the effect of al-
lergy status in both asthma and control groups. A P-value of
<0.05 was considered to be statistically significant.Figure 1 MCA0e3 (A), MCA0e5.2 (B) and NCV0e3 (C) in the
asthmatic patients (white bars) and controls (grey bars). Values
presented as mean, 95% CI. Abbreviations: MCA Z minimum
cross sectional area; NCVZ nasal cavity volume; 0e3Z 0e3 cm
behind the nasal orifice; 0e5.2 Z 0e5.2 cm behind the nasal
orifice.
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tistics, version 18 for Windows (SPSS Inc., Chicago, IL, USA).
Results
The demographic data are presented in Table 1. The mean
(95% CI) baseline FEV1 was significantly lower in asthma pa-
tients than controls [2.79 (2.61e2.97) vs 3.46 (3.26e3.65) l,
P < 0.001].
Rhinometry measurements
Data on rhinometric variables at baseline and after topical
xylometazoline, calculated as the NCI, are presented in
Table 2.
MCA0e3, MCA0e5.2 and NCV0e3 were significantly lower in
asthmatics than in controls (Fig. 1). In the asthma group the
MCA for the whole nasal airway (MCA0e5.2) was located in
the anterior region (MCA0e3) in 95% and more posteriorly
(MCA3e5.2) in 5% of subjects. In the control group the
MCA0e5.2 was located in the anterior region (MCA0e3) in 98%
and more posteriorly (MCA3e5.2) in 2% of the subjects.
MCA0e2, MCA2e4, MCA0e4 and NCV0e2 were significantly
lower in asthmatics than in controls (data not shown). The
lowest value of the MCA was located at 2e4 cm from the
nasal orifice in 59 and 61% of asthmatics and controls,
respectively.
NCI was not significantly different between the groups.
Inspiratory flow
The mean (95% CI) PNIF was significantly lower in the
asthma group compared to the control group [84 (78e89) vs
102 (98e106) l/min, P < 0.001].
The effect of xylometazoline was significantly greater in
asthmatics than in controls (Table 2).
Allergy
AR variables and PNIF were not significantly different in
asthmatics and controls when analyzed by allergy status
(Fig. 2).Table 2 Acoustic rhinometry and peak nasal inspiratory flow re
Measurement level Acoustic rhinometry
Asthmatics (N Z 87) Controls (N Z 93)
MCA0e3 0.47 (0.12) 0.52 (0.12)
MCA3e5.2 0.89 (0.35) 0.92 (0.27)
MCA0e5.2 0.47 (0.12) 0.52 (0.12)
NCV0e3 2.35 (0.46) 2.53 (0.42)
NCV3e5.2 2.95 (1.16) 2.97 (0.88)
NCV0e5.2 5.30 (1.45) 5.50 (1.20)
PNIF 84 (24.4) 102 (18.8)
Data presented as mean (SD). Abbreviations: MCAZ minimum cross se
index; SDZ standard deviation; 0e3Z 0e3 cm behind the nasal orific
behind the nasal orifice; PNIF Z peak nasal inspiratory flow.Discussion
This study demonstrates that the nasal airway, when
assessed by cross sectional area and volume, is significantly
smaller in asthmatics than controls, and that the cross
sectional area is at its minimum at 2e3 cm from the nasal
orifice in both groups. The NCI with regard to AR mea-
surements is not significantly different between the two
groups, but there is a significant improvement in NCI for
PNIF in the asthmatics. AR and PNIF measurements are not
significantly different in allergic and non allergic subjects in
either group.
MCA and NCV in asthmatics have been studied previously
by two other groups [10,14]. Our finding of a lower MCA at
0e4 cm and NCV at 0e3 cm is in accordance with that of
Hellgren et al. They found a decrease in the cross-sectional
area at 4 cm and in the volume between 3.3 and 4 cm in the
asthma group compared with healthy controls. In contrast,
Wa˚linder et al. did not find any significant difference in
minimum cross sectional area and intranasal volume
measured between 0 and 5.2 cm in 41 asthmatics and
healthy controls.
The location of the MCA in both asthmatics and controls
appears to correspond with the location of the internal
nasal valve. The latter consists of 4 distinct compartments
of airflow resistors: two structural e the cartilaginous
termination of the nasal vestibule and the bony entrance to
the cavum, and two mucovascular compartments e the
inferior turbinate and the septal erectile body, both char-
acterised by numerous venous sinusoids [15]. The magni-
tude of airflow is determined by the shape and dimensions
of these anatomicalephysiological narrowings and by
airflow velocity [16]. In the present study, it is unlikely that
the reduced nasal patency in asthmatics is due to conges-
tion of the venous sinusoids. The decongestive effect of
xylometazoline is achieved by vasoconstriction of the nasal
venous sinusoids via stimulation of a-2 receptors [17], and
there was no significant difference in the NCI for MCA and
NCV between the two groups. Thus, the most likely expla-
nation for the differences in nasal patency is the presence
of an inflammatory cell substrate, subepithelial oedema
and fibrous tissue in those with asthma which is not influ-
enced by decongestive measures. Nasal mucosal inflam-
mation with eosinophilic infiltration has been reported incordings at baseline and nasal congestion index.
Nasal congestion index
P Asthmatics (N Z 85) Controls (N Z 93) P
0.01 0.12 (0.18) 0.09 (0.17) 0.17
0.57 0.65 (0.47) 0.67 (0.43) 0.77
<0.01 0.13 (0.19) 0.09 (0.17) 0.10
<0.01 0.09 (0.10) 0.09 (0.10) 0.74
0.89 0.43 (0.47) 0.43 (0.34) 0.95
0.32 0.25 (0.24) 0.26 (0.19) 0.65
<0.001 0.14 (0.20) 0.06 (0.11) <0.01
ctional area; NCVZ nasal cavity volume; NCIZ nasal congestion
e; 3e5.2Z 3e5.2 cm behind the nasal orifice; 0e5.2Z 0e5.2 cm
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flicting results concerning structural changes such as basal
membrane thickening in the nasal mucosa of patients with
asthma [19,20]. Other structural factors that may represent
a difference are nasal polyps, CRS, previous nasal surgery
and chronic immunological/inflammatory conditions, but
subjects with these abnormalities were excluded from the
present study.
Nasal airway patency depends on the geometry of the
airway, airflow and resistance. According to Poiseuille’s
law flow is directly proportional to the difference in
pressure multiplied by the radius raised to the fourthFigure 2 MCA0e3 (A), MCA0e5.2 (B) and NCV0e3 (C) in the
allergic asthmatic patients, non-allergic asthmatic patients,
allergic controls and non-allergic controls. Values presented as
mean, 95% CI. Abbreviations: MCA Z minimum cross sectional
area; NCV Z nasal cavity volume; 0e3 Z 0e3 cm behind the
nasal orifice; 0e5.2 Z 0e5.2 cm behind the nasal orifice.power. A minimal decrease in the radius of the nasal
airway will thus result in a significant reduction in flow
[21], illustrated in this study by a reduced MCA and a
consequently reduced PNIF in the asthma group. In con-
stricted areas, velocity increases and a relatively negative
pressure is generated [21]. These phenomena are seen in
the internal nasal valve which represents the flow-limiting
region or the bottle-neck area of the nasal cavity. Although
the relative changes in NCI MCA in the asthmatic and
control groups are equal the MCA in the asthma group is
still smaller and this may explain the persistent difference
in PNIF after decongestion. In addition to structural and
mucosal characteristics, other factors may control nasal
airflow. A reduction in forced inspiration may give a
reduced stimulation of the sensors for nasal airflow. When
the breathing effort is sub maximal or intrapulmonary dy-
namic resistance is increased, reduced PNIF can give a
misleading impression of nasal obstruction. It has also been
suggested that asthmatics generally may just have a
different subjective perception of nasal obstruction that
may explain their oronasal breathing [22].
Breathing is a dynamic process, with turbulent and
laminar flow occurring simultaneously in different parts of
the nasal passage. AR is static in nature and thus has limi-
tations with regard to detecting dynamic changes. On the
other hand, PNIF is effort dependent, but the non-rigidity
of the ala nasi may induce dynamic collapse in the
compliant part of the external nose. Despite a maximum
limitation of PNIF recordings to 120 l/min, we demon-
strated highly significant differences between asthmatics
and controls. In addition, PNIF values above 120 l/min are
only of minor clinical interest because such high peak flows
generally exclude nasal obstruction [23,24].
We found that both allergic and non-allergic asthmatics
have significantly smaller MCA0e5.2 and NCV0e3 compared
to their respective controls. Other studies have reported
that both allergic and non-allergic asthma patients had
more nasal symptoms and mucosal abnormalities in the
nose and had elevated levels of inflammatory markers in
nasal secretions, together with a significant impairment of
quality of life and reduced inspiratory nasal airflow
compared to non-asthmatics [4,6]. This highlights the
importance of a thorough oto-rhino-laryngological exami-
nation and evaluation in all asthma patients, beyond the
scope of allergy.
As alterations in nasal cavity geometry and airflow may
compromise lung function, the results of the present
investigation indicate a need for nasal biopsy studies in
asthmatics to further understand nasal obstruction in these
patients. It also indicates a need for considering medical
and surgical interventions to open the nose for the benefit
of the lungs.Conflicts of interest
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